OncoMatch/Clinical Trials/NCT06455358
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
Is NCT06455358 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies 61Cu-NODAGA-LM3 for neuroendocrine tumors.
Treatment: 61Cu-NODAGA-LM3 — The goal of this monocentric, open-label, randomized-controlled, reader-blind clinical study is to assess the safety of the radiolabeled somatostatin receptor ligand, 61Cu-NODAGA-LM3, and its sensitivity in comparison to the standard of care, 68Ga-DOTATOC, for PET/CT imaging in patients with well differentiated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Prior therapy
Cannot have received: radiopharmaceutical
Prior or planned administration of a radiopharmaceutical within 8 half-lives of the radionuclide used on such radiopharmaceutical including at any time during the current study
Cannot have received: active anti-tumor treatment
Exception: continuation of long acting somatostatin analogues
Initiation or continuation of active anti-tumor treatment between 61Cu-NODAGA-LM3 and 68Ga-DOTATOC PET/CT, except continuation of long acting somatostatin analogues
Lab requirements
Kidney function
estimated egfr (ckd-epi) ≥ 45 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify